Cancer immunotherapy candidate provokes powerful dual response in cancer and immune cells
Cancer immunotherapy drugs called PD-1 inhibitors are widely used to stimulate the immune system to fight cancer, but many patients either don’t respond or develop resistance to them. A new small-molecule drug candidate being tested in an early-stage clinical trial aims to improve patient responses to immunotherapy. Now scientists have shown, in a study published today in Nature, that the small molecule works through two different mechanisms to slow tumor growth and increase survival in lab animals. Researchers from the Tumor ...
Read the release










